Drugs that target peptide hormone receptors are of great interest in the treatment of type 2 diabetes. In spite of limited data and vast design spaces, a bespoke computational pipeline has designed peptides that target two receptors with high potency.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Couzin-Frankel, J. Science 382, 1226–1227 (2023).
Schauer, P. R. et al. NEJM 376, 641–651 (2017).
Puszkarska, A. M. et al. Nat. Chem. https://doi.org/10.1038/s41557-024-01532-x (2024).
Campbell, J. E. & Drucker, D. J. Cell Metab. 17, 819–837 (2013).
Jastreboff, A. M. et al. NEJM 387, 205–216 (2022).
Nestor, J. J. et al. Sci. Rep. 12, 6666 (2022).
Markey, C. et al. Nat. Comput. Sci. 4, 96–103 (2024).
Reker, D. Drug Discov. Today Technol. 32–33, 73–79 (2019).
Coskun, T. et al. Cell Metab. 34, 1234–1247 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D. R. acts as a consultant to the pharmaceutical and biotechnology industry, as a mentor for Start2, and serves on the scientific advisory board of Areteia Therapeutics. C. E. M. declares no competing interests.
Rights and permissions
About this article
Cite this article
Markey, C.E., Reker, D. Machine learning trims the peptide drug design process to a sweet spot. Nat. Chem. 16, 1394–1395 (2024). https://doi.org/10.1038/s41557-024-01610-0
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41557-024-01610-0
